Absorption of Drugs via Passive Diffusion and Carrier-Mediated Pathways

Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications

Volumn , Issue , 2011, Pages 63-75

  Park, Miki Susanto ^a   Chang, Jae H ^b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b GENENTECH INC   (United States)

Author keywords

Drug absorption via carrier mediated process drug drug interaction, dose dependent pharmacokinetics; Drug absorption via passive diffusion, carrier mediated pathways oral route, convenient and economical; Passive diffusion, solute molecules passing through random molecular motion

Indexed keywords

EID: 84885825119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118067598.ch6     Document Type: Chapter

References (38)

1. Amidon GL and Sadee W (1999) Membrane Transporters as Drug Targets. Kluwer Academic/Plenum Publishers, New York.
2. Bourdet DL, Pollack GM, and Thakker DR (2006) Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm Res 23:1178-1187.
3. Chang JH, Yoo P, Lee T, Klopf W, and Takao D (2009) The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe. Mol Pharm 6:1216-1227.
4. Cong D, Doherty M, and Pang KS (2000) A new physiologically based, segregated-flow model to explain route-dependent intestinal metabolism. Drug Metab Dispos 28:224-235.
5. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, and Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871.
6. Dobson PD and Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7:205-220.
7. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
8. Dressman JB, Amidon GL, and Fleisher D (1985) Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci 74:588-589.
9. Fisher MB, Campanale K, Ackermann BL, VandenBranden M, and Wrighton SA (2000) In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metab Dispos 28:560-566.
10. Fujioka Y, Metsugi Y, Ogawara K, Higaki K, and Kimura T (2008) Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. Int J Pharm 352:36-43.
11. Garrett RH and Grisham CM (2004) Biochemistry. Saunders College Publishing, Orlando, FL.
12. Giacomini KM and Sugiyama Y (2006) Membrane transporters and drug response, in: Goodman & Gilman's the Pharmacological Basis of Therapeutics (Goodman LS, Gilman A, Brunton LL, Lazo JS, and Parker KL, eds.), pp. 41-70, McGraw-Hill, New York.
13. Hagenbuch B and Meier PJ (2003) The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609:1-18.
14. Hediger MA, Romero MF, Peng JB, Rolfs A, Takanaga H, and Bruford EA (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Introduction. Pflugers Arch 447:465-468.
15. Hoener B-A and Benet LZ (2002) Factors influencing drug absorption and drug availability, in: Modern Pharmaceutics (Banker GS and Rhodes CT, eds.), pp. 145-186, Marcel Dekker, New York.
16. Ito K, Suzuki H, Horie T, and Sugiyama Y (2005) Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res 22:1559-1577.
17. Karlsson J, Ungell A, Grasjo J, and Artursson P (1999) Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux. Eur J Pharm Sci 9:47-56.
18. King AE, Ackley MA, Cass CE, Young JD, and Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416-425.
19. Li X and Jasti B (2005) Theory and applications of diffusion and dissolution, in: Theory and Practices of Contemporary Pharmaceutics (Ghosh TK and Jasti BR, eds.), pp 197-216, CRC Press, Boca Rotan, FL.
20. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
21. Oh DM and Amidon GL (1999) Overview of membrane transport. Pharm Biotechnol 12:1-27.
22. Oh DM, Han HK, and Amidon GL (1999a) Drug transport and targeting. Intestinal transport. Pharm Biotechnol 12:59-88.
23. Oh D-M, Han H-K, and Amidon GL (1999b) Drug transport and targeting, in: Membrane Transporters as Drug Targets (Amidon GL and Sadee W, eds.), Kluwer Academic/Plenum Publishers, New York.
24. Piyapolrungroj N, Zhou YS, Li C, Liu G, Zimmermann E, and Fleisher D (2000) Cimetidine absorption and elimination in rat small intestine. Drug Metab Dispos 28:65-72.
25. Scheepers A, Joost HG, and Schurmann A (2004) The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 28:364-371.
26. Seatter MJ and Gould GW (1999) The mammalian facilitative glucose transporter (GLUT) family. Pharm Biotechnol 12:201-228.
27. Smith PL (2000) The role of permeability studies in preclinical evaluation, in: Oral Drug Absorption (Dressman JB and Lennernas H, eds.), Marcel Dekker, New York, NY.
28. Stenberg P, Bergstrom CA, Luthman K, and Artursson P (2002) Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmacokinet 41:877-899.
29. Sugawara M, Huang W, Fei YJ, Leibach FH, Ganapathy V, and Ganapathy ME (2000) Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2. J Pharm Sci 89:781-789.
30. Tam D, Tirona RG, and Pang KS (2003) Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 31:373-383.
31. Thomas VH, Bhattachar S, Hitchingham L, Zocharski P, Naath M, Surendran N, Stoner CL, and El-Kattan A (2006) The road map to oral bioavailability: an industrial perspective. Expert Opin Drug Metab Toxicol 2:591-608.
32. Tozer TN and Rowland M (2006) Introduction to Pharmacokinetics and Pharmacodynamics: The Quantitative Basis of Drug Therapy, Lippincott Williams & Wilkins, Philadelphia, PA.
33. Trevaskis NL, Charman WN, and Porter CJ (2008) Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev 60:702-716.
34. Ungell AL, Nylander S, Bergstrand S, Sjoberg A, and Lennernas H (1998) Membrane transport of drugs in different regions of the intestinal tract of the rat. J Pharm Sci 87:360-366.
35. Wu CY and Benet LZ (2005) Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
36. Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, and Yu LX (2007) Biopharmaceutics classification of selected betablockers: solubility and permeability class membership. Mol Pharm 4:608-614.
37. Yu LX and Amidon GL (2000) Analytical solutions to mass transfer, in: Transport Processes in Pharmaceutical Systems (Amidon GL, Lee PI, and Topp EM, eds.), pp 23-54, Marcel Dekker, New York.
38. Zhao YH, Le J, Abraham MH, Hersey A, Eddershaw PJ, Luscombe CN, Butina D, Beck G, Sherborne B, Cooper I, and Platts JA (2001) Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J Pharm Sci 90:749-784.